Finance

Beta
Lists
ALNOV:EPA
Novacyt SA
€ ०.५९
+१.०३%
(+०.००६०) 1D
मे २९, १७:३५:२० GMT+२  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNOV...
Open
€ ०.६०
High
€ ०.६४
Low
€ ०.५७
Mkt. cap
४.३१ करोड
Avg. vol.
२२.५३ लाख
Volume
११.७१ लाख
52-wk high
€ १.०४
52-wk low
€ ०.२९
EPS
-€ ०.३८
Shares outstanding
७.२६ करोड
No. of employees
२२४
Open
€ ०.६०
High
€ ०.६४
Low
€ ०.५७
Mkt. cap
४.३१ करोड
Avg. vol.
२२.५३ लाख
Volume
११.७१ लाख
52-wk high
€ १.०४
52-wk low
€ ०.२९
EPS
-€ ०.३८
Shares outstanding
७.२६ करोड
No. of employees
२२४
News stories
From sources across the web
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees२२४
Founded२००६ जुलाई ३
Headquarters-
Sector-
Websitenovacyt.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
४८.९६ लाख
४८.९६ लाख
५१.१८ लाख
५१.१८ लाख
Cost of goods sold
१६.४३ लाख
१६.४३ लाख
२६.१४ लाख
२६.१४ लाख
Cost of revenue
१६.४३ लाख
१६.४३ लाख
२६.१४ लाख
२६.१४ लाख
Research and development expenses
१०.२२ लाख
१०.२२ लाख
१०.३४ लाख
१०.३४ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५५.०८ लाख
५५.०८ लाख
४६.८८ लाख
४६.८८ लाख
Operating expense
६४.३२ लाख
६४.३२ लाख
५५.४२ लाख
५५.४२ लाख
Total operating expenses
८०.७५ लाख
८०.७५ लाख
८१.५६ लाख
८१.५६ लाख
Operating income
-३१.७८ लाख
-३१.७८ लाख
-३०.३८ लाख
-३०.३८ लाख
Other non operating income
-३१.०० हजार
-३१.०० हजार
१७.२४ लाख
१७.२४ लाख
EBT including unusual items
-३५.१३ लाख
-३५.१३ लाख
-१.०२ करोड
-१.०२ करोड
EBT excluding unusual items
-३१.२० लाख
-३१.२० लाख
-२५.१८ लाख
-२५.१८ लाख
Income tax expense
-१.३४ लाख
-१.३४ लाख
-१८.१४ लाख
-१८.१४ लाख
Effective tax rate
३.८०%
३.८०%
१७.८५%
१७.८५%
Other operating expenses
-९७.५० हजार
-९७.५० हजार
-१.८० लाख
-१.८० लाख
Net income
-३१.७१ लाख
-३१.७१ लाख
-८२.७० लाख
-८२.७० लाख
Net profit margin
-६४.७६%
-६४.७६%
-१६१.६०%
-१६१.६०%
Earnings per share
-
-
-
-
Interest and investment income
१.७७ लाख
१.७७ लाख
१.७३ लाख
१.७३ लाख
Interest expense
-१.५४ लाख
-१.५४ लाख
-१९.१० लाख
-१९.१० लाख
Net interest expenses
२३.०० हजार
२३.०० हजार
-१७.३६ लाख
-१७.३६ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२१.६६ लाख
-२१.६६ लाख
-१९.९१ लाख
-१९.९१ लाख
Gain or loss from assets sale
-१.४८ लाख
-१.४८ लाख
-३.०० हजार
-३.०० हजार
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer